 | Up a level |
Journal Article
Deckert, M., Engert, A., Brueck, W., Ferreri, A. J. M., Finke, J., Illerhaus, G., Klapper, W., Korfel, A., Kueppers, R., Maarouf, M., Montesinos-Rongen, M., Paulus, W., Schlegel, U., Lassmann, H., Wiestler, O. D., Siebert, R. and DeAngelis, L. M. (2011). Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia, 25 (12). S. 1797 - 1808. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924
Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosee, P., Binder, M., Fabbri, A., Torri, V., Minacapelli, E., Falautano, M., Ilariucci, F., Ambrosetti, A., Roth, A., Hemmaway, C., Johnson, P., Linton, K. M., Pukrop, T., Gorlov, J. S., Balzarotti, M., Hess, G., Keller, U., Stilgenbauer, S., Panse, J., Tucci, A., Orsucci, L., Pisani, F., Levis, A., Krause, S., Schmoll, H. J., Hertenstein, B., Zaccaria, A., Guarini, A., Atta, J., Bassan, R., Cervetti, J., Elter, T., Enggaard, L., Haenel, M., Kneba, M., Liberati, M., Martelli, M., Martens, U., Morra, E., Pinto, A., Zaja, F., Ponzoni, M., Deckert, M., Politi, L. S., Finke, J., Reni, M., Cavalli, F., Zucca, E. and Illerhaus, G. (2017). Autologous stem cell transplantation (ASCT) or whole-brain radiotherapy (WBRT) as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary cns lymphoma (PCNSL): results of the IELSG32 randomized Phase II Trial. Bone Marrow Transplant., 52. S. S96 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Fritsch, K., Kasenda, B., Schorb, E., Hau, P., Bloehdorn, J., Moehle, R., Loew, S., Binder, M., Atta, J., Keller, U., Wolf, H-H, Krause, S. W., Hess, G., Naumann, R., Sasse, S., Hirt, C., Lamprecht, M., Martens, U., Morgner, A., Panse, J., Frickhofen, N., Roeth, A., Hader, C., Deckert, M., Fricker, H., Ihorst, G., Finke, J. and Illerhaus, G. (2017). High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia, 31 (4). S. 846 - 853. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Haas, M., Waldschmidt, D., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R. J. C., Malfertheiner, P., Illerhaus, G., Kubicka, S., Held, S., Westphalen, C. B., Kruger, S., Boeck, S. and Heinemann, V. (2018). Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT). Ann. Oncol., 29. S. 243 - 244. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Haas, M., Waldschmidt, D. T., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., von Weikersthal, L. Fischer, Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R., Malfertheiner, P., Illerhaus, G., Kubicka, S., Abdul-Ahad, A., Snijder, R., Kruger, S., Westphalen, C. B., Held, S., Von Bergwelt-Baildon, M., Boeck, S. and Heinemann, V (2021). Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method. Eur. J. Cancer, 146. S. 95 - 107. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Hecht, M., Hahn, D., Beutner, D., Reichert, D., Goehler, T., Wurm, R., Welslau, M., Renziehausen, L., Balermpas, P., Bergmann, T., Assmann, M., Belka, C., Orlowski, K., Finzsch, M., Illerhaus, G. and Fietkau, R. (2016). Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial). Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Hecht, My, Hahn, D., Beutner, D., Reichert, D., Goehler, T., Wurm, R., Welslau, M., Renziehausen, L., Balermpas, P., Bergmann, T., Assmann, M., Belka, C., Orlowski, K., Finzsch, M., Illerhaus, G. and Fietkau, R. (2016). Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial). Oncol. Res. Treat., 39. S. 171 - 172. BASEL: KARGER. ISSN 2296-5262
Illerhaus, G., Cwynarski, K., Pulczynski, E., Ponzoni, M., Deckert, M., Politi, L. S., Fox, C. P., La Rose, P., Ambrosetti, A., Roeth, A., Hemmaway, A., Ilariucci, F., Linton, K. M., Soffietti, R., Pukrop, T., Binder, M., Balzarotti, M., Fabbri, A., Johnson, P., Gorlov, J. S., Cavalli, F., Finke, J., Schorb, E., Reni, M., Zucca, E. and Ferrer, A. J. M. (2015). Improved outcome with addition of thiotepa and rituximab to methotrexate and cytarabine in primary cns lymphoma: Results of the first randomization of the IELSG-32 trial. Oncol. Res. Treat., 38. S. 177 - 178. BASEL: KARGER. ISSN 2296-5262
Schiemenz, C., Lueken, S., Klassen, A. M., Ranjbar, M., Illerhaus, G., Fend, F., Heindl, L. M., Chronopoulos, A., Grisanti, S. and Kakkassery, V (2022). Clinical procedures for intraocular lymphomas. Ophthalmologie, 119 (7). S. 675 - 686. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7218